GlassScriptPhysician profile
Toby J Katz
NPI 1336159052
$2,940.67
in general payments reported to CMS, 2019-2025
28 companies · $722 in 2025
The $722 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $612 · 2020: $92.78 · 2021: $194 · 2022: $614 · 2023: $424 · 2024: $282 · 2025: $722.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,428.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,427.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $957.64 | 2019-2025 | |
| Janssen Biotech, INC. | $328.73 | 2019-2024 | Stelara, Tremfya, Remicade |
| Gilead Sciences, INC. | $204.38 | 2019-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $177.54 | 2019-2025 | Entyvio |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $168.84 | 2019-2025 | Xifaxan |
| Intercept Pharmaceuticals, INC. | $155.22 | 2022-2023 | Ocaliva |
| Daiichi Sankyo INC. | $110.46 | 2021-2022 | |
| Madrigal Pharmaceuticals | $104.72 | 2025 | Rezdiffra |
| Merck Sharp & Dohme LLC | $96.47 | 2019-2023 | Dificid |
| Exact Sciences Corporation | $58.90 | 2023-2024 | Cologuard Collection Kit |
| Ardelyx, INC. | $56.87 | 2025 | Ibsrela |
| Lilly USA, LLC | $54.65 | 2025 | Omvoh |
| Vivus LLC | $47.92 | 2021-2025 | Pancreaze |
| Ipsen Biopharmaceuticals, INC | $46.19 | 2025 | Iqirvo |
| Braintree Laboratories, INC. | $42.03 | 2019-2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Qol Medical, LLC | $39.39 | 2019-2023 | Sucraid |
| Pfizer INC. | $36.97 | 2019 | |
| Celgene Corporation | $35.20 | 2021-2023 | Zeposia |
| Ferring Pharmaceuticals INC. | $34.83 | 2019 | |
| Romark Laboratories, Lc | $33.62 | 2019 | |
| Endo Pharmaceuticals INC. | $28.30 | 2019 | |
| Allergan, INC. | $22.44 | 2020 | |
| Olympus America INC. | $22.07 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $20.72 | 2022 | |
| Phathom Pharmaceuticals, INC. | $15.72 | 2024 | Voquezna |
| Nestle Healthcare Nutrition INC. | $14.70 | 2022 | |
| Medtronic, INC. | $13.11 | 2024 | Gi Genius |
| Alnylam Pharmaceuticals INC. | $13.04 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Toby Katz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.